12,254 reports of this reaction
3.5% of all USTEKINUMAB reports
#2 most reported adverse reaction
OFF LABEL USE is the #2 most commonly reported adverse reaction for USTEKINUMAB, manufactured by Janssen Biotech, Inc.. There are 12,254 FDA adverse event reports linking USTEKINUMAB to OFF LABEL USE. This represents approximately 3.5% of all 346,490 adverse event reports for this drug.
USTEKINUMAB has an overall safety score of 78 out of 100. Patients taking USTEKINUMAB who experience off label use should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
OFF LABEL USE is moderately reported among USTEKINUMAB users, representing a notable but not dominant share of adverse events.
In addition to off label use, the following adverse reactions have been reported for USTEKINUMAB:
The following drugs have also been linked to off label use in FDA adverse event reports:
OFF LABEL USE has been reported as an adverse event in 12,254 FDA reports for USTEKINUMAB. This does not prove causation, but indicates an association observed in post-market surveillance data.
OFF LABEL USE accounts for approximately 3.5% of all adverse event reports for USTEKINUMAB, making it one of the most commonly reported side effect.
If you experience off label use while taking USTEKINUMAB, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.